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87Higher infliximab trough levels are associated with clinical and endoscopic remission in pa-







95We performed a substudy of the TAILORIX trial (patients with active luminal CD in Europe,
treated with infliximab), analyzing baseline and week 54 magnetic resonance enterography
(MRE) data. MREs were scored using the MaRIA score by blinded central readers. Radiologic
response and remission were defined, based on MaRIA criteria in all segments, as scores below
11 and 7, respectively. We collected data on infliximab trough levels, biomarkers, and endo-
scopic endoscopy findings. Our primary aim was to evaluate pharmacodynamic features asso-
ciated with radiologic response and remission, based on MRE assessments at baseline and at 54










106We analyzed data from 36 patients (50% female; median age 35.7 years; interquartile age range,
25.6–48.6 years; median disease duration, 1.5 months; interquartile duration range, 0.6–22.4
months). At week 54 of treatment, 36.4% of patients had a radiologic response, 30.3% of patients
were in remission, and 71% had endoscopic features of remission. At baseline, there was a
correlation between the CD endoscopic index of severity and MaRIA scores (k [ 0.46;
P [ .008), but we found no correlation at week 54 (k [ 0.06; P [. 75). Radiologic remission
correlated with infliximab trough level at week 14 (P [ .049) when the infliximab trough level
cut-off value was set at 7.8 mg/ml (area under the curve, 0.74; 75% sensitivity; 86% specificity;
90% negative predictive value; 57% positive predictive value). Radiologic response correlated
with infliximab trough levels at week 14 (P[ .048) when the infliximab trough level cut-off value
was set at 7.8 mg/ml (area under the curve, 0.73; 70% sensitivity; 90% specificity; 86% negativeer: CD, Crohn’s disease; CDEIS, Crohn’s
everity; CR, central reader; FISP, fast im-
ssion; ICC, intraclass correlation; IQR,
gnetic Resonance Index of Activity; MRE,
raphy; PEG, polyethylene glycol; ROC,
ics; TAILORIX, randomized controlled trial
investigating tailored treatment with infliximab for active luminal Crohn’s
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predictive value; 78% positive predictive value) and with continuous pharmacologic evidence of
response (infliximab trough levels above 5.0 mg/ml at all time points) (P [ .034).177
178CONCLUSIONS:
179In a substudy of data from the TAILORIX trial of patients with active luminal CD, we identified a



































217Crohn’s disease (CD) is an inflammatory diseasethat affects the gastrointestinal tract over a vari-
able extent. The major clinical characteristic that dis-
criminates CD from ulcerative colitis is the transmural
nature of the inflammation.1 The current gold standard
to assess disease activity in CD is endoscopy.2 The
regression of intraluminal lesions (ie, endoscopic
remission) is associated with favorable long-term out-
comes in CD.3 During the last decades newer modalities
to assess also this transmural aspect of disease activity in
CD emerged.4 Magnetic resonance enterography (MRE)
provides an assessment of the luminal, mural, and extra-
luminal manifestation of CD. Disease activity scores have
been developed to systematically assess the severity of
inflammation on MRE.5,6 It has been documented that
as early as week 2 after the start of infliximab, improve-
ment in disease activity based on MRE can be detected.7
Only a minority of patients achieve complete disappear-
ance of inflammatory lesions on MRE during mainte-
nance therapy with infliximab.7 Radiologic response
has also been associated with better outcomes in CD pa-
tients, and recent evidence suggests that radiologic heal-
ing might be the ultimate therapeutic goal in CD.8–11 It is
well-established that there is a clear exposure-response
relationship for infliximab, with higher infliximab trough
levels being associated with endoscopic remission.12
Currently no data are available on the effect of infliximab
on radiologic remission in patients with CD.
Therefore the aim of this study was to evaluate the
pharmacodynamics of infliximab in radiologic response
and remission in patients with CD on the basis of MRE
assessments at baseline and at 54 weeks after initiation

















The multicenter (27 centers in Belgium, France, and
the Netherlands) randomized controlled trial investi-
gating tailored treatment with infliximab for active
luminal Crohn’s disease TAILORIX aimed to explore the
role of tailored treatment with infliximab in biological
naive patients with active luminal CD.13 In total, 167
patients were screened, and 122 patients with moderate
to severely active CD (Crohn’s disease activity index
220–450) were started on infliximab in combinationFLA 5.6.0 DTD  YJCGH57170_proof with an immunomodulator. Patients were randomized at
week 14 after standard induction regimen (infliximab 5
mg/kg week 0-2-6) to receive 1 of 3 regimens of
monitoring-based dosage adjustments, on the basis of
clinical symptoms only or on a combination of clinical
symptoms, C-reactive protein levels, fecal calprotectin
levels, and infliximab trough levels.
At weeks 0, 12, and 54, patients underwent a pre-
scheduled ileocolonoscopy. The endoscopic activity of
disease was scored blindly on the basis of the Crohn’s
Disease Endoscopic Index of Severity (CDEIS).14 MREs
were performed in a priori selected centers (n ¼ 5).
Selection was based on ability to perform high quality
MRE and recruitment potential. Patients consented
separately to participate in the MRE substudy. These
patients (representing >50% of the total number of
included patients per selected site) underwent an MRE at
week 0 and week 54 or at the early termination visit. For
the current analysis all patients with at least 1 MRE in
the TAILORIX study were included, irrespective of
treatment group to which the patients were assigned in
the study. Clinical, biochemical, endoscopic, and phar-
macologic data from the TAILORIX trial were available
for these patients.Magnetic Resonance Imaging Methodology
MRE was performed in 5 of the 27 participating
centers. The MRE was preferentially performed on the
same day as the ileocolonoscopy. The patient had nil per
mouth on the day of the examination. Forty-five minutes
before the MRE the patient ingested z1500 mL poly-
ethylene glycol (PEG) 4000 (or 3350), with additional
oral ingestion of 500 mL water or PEG 15 minutes before
examination. At the start of the examination 0.5 mg
glucagon was administrated intravenously just before
intravenous injection of gadolinium. The patient was
placed in procubitus position with a phased array body
coil. The following sequences were performed: coronal
and axial true fast imaging with steady-state precession
(true FISP) sequence, with breath hold, without fat
suppressed, and with a slice thickness of 5 mm and a
skip of 0 mm; coronal true FISP sequence, with breath
hold, with fat suppression, and with a slice thickness of 5
mm and a skip of 0 mm; coronal and axial T2 weighted
images using single shot fast spin echo sequence with a
slice thickness of 5 mm and a skip of 0 mm; and coronal
3-dimensional T1-weighted gradient echo sequence with6 August 2020  6:29 am  ce CLR
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What You Need to Know
Background
Increased exposure to infliximab results in higher
rates of endoscopic healing in patients with Crohn’s
disease (CD). Radiologic remission, determined by
magnetic resonance enterography, associates with
long-term outcomes but is difficult to achieve.
Findings
Radiologic remission was achieved in approximately
one-third of patients with luminal CD treated with
infliximab. An infliximab trough level of 7.8 mg/mL at
the end of induction therapy was associated with
radiologic response and remission.
Implications for patient care
Radiologic healing is difficult but achievable for pa-
tients with luminal CD. Monitoring trough levels of
infliximab can guide treatment, and optimizing
dosing during induction therapy could improve long-
term outcomes.




















































































































348breath hold with a slice thickness of 2–3 mm. Sixty sec-
onds after injection of gadolinium (0.1 mmol/kg), coro-
nal and axial gadolinium enhanced 3-dimensional
gradient echo sequence with breath hold, with a slice
thickness of 2–3 mm was acquired. Axial 2-dimensional
T1-weighted gradient echo sequence after injection of
gadolinium with a slice thickness of 5 mm and a skip of
0 mm was acquired. The images were archived on a Data
on Picture Archiving and Communication System and
compact disk.
Magnetic Resonance Enterography Central
Reading
All MRE images were de-identified. The MRE studies
were centrally reviewed by 6 different central readers
(CRs) as prespecified in the protocol; all of them had
more than 10 years of experience in abdominal imaging.
The MRE studies were assigned randomly to the
different CRs. Every CR was blinded to patient data and
clinical information. Every CR scored z24 MRE studies
randomly; in this way all MREs were randomly scored
twice by 2 different CRs. The MREs were scored by using
the Magnetic Resonance Index of Activity (MaRIA).5 The
MaRIA index was calculated by using the previously
published formula: 1.5  wall thickening (mm) þ 0.02 
RCE (relative contrast enhancement) þ 5  edema þ
10  ulcers.5,15 Global MaRIA score is based on terminal
ileum and all colonic segments. For the calculation of the
MaRIA index an electronic clinical research form was
used that automatically calculated the score. The
threshold for discrepancy between 2 readers was set at a
difference of 1.5 points in the MaRIA index per segment,
if active disease was present (MaRIA 7 in at least 1
segment). If there was a discrepancy between 2 CRs in at
least 1 segment (independent of any discrepancy in the
global MaRIA index), then the images were adjudicated
by a third independent CR (JR). In case no adjudication
was needed, then the mean of the scores of the 2 CRs was
used. The global MaRIA was the sum of the mean scores
per segment (in case no adjudication was needed) and/
or the adjudicated scores per segment. Global radiologic
response and remission were defined as MaRIA score in
all segments <11 and <7, respectively, in patients with
active radiologic disease at baseline. Segmental radio-
logic response and remission were defined as MaRIA
score in one segment <11 and <7, respectively.16
Statistical Analysis
Statistical analysis was done by using SPSS 26.0 (IBM
Corp, Armonk, NY) and Graphpad Prism 5.01 (GraphPad
Software, San Diego, CA). Continuous variables with non-
normal distribution are described as medians with
interquartile range (IQR). Categorical variables are
described as percentages. For time independent evalua-
tion of continuous variables we used the Mann-WhitneyFLA 5.6.0 DTD  YJCGH57170_proof  6 August 2020  6:29 am  ce CLRtest, and for categorical variables we used the c2 tests
(univariate analysis). Correlation with outcomes was
based on patients with radiologic active disease at
baseline (extrapolated for missing MRE baseline) and
available MRE at week 54 (n ¼ 31). The Wilcoxon
signed-rank test was performed to test differences be-
tween 2 measurements at different time points in the
same patient. Intraclass correlation (ICC) (2-way random
model and absolute agreement type) was used to test the
inter-rater reliability of a continuous score (MaRIA
score).17 For this we categorized the continuous values
(severe partial MaRIA 11; active partial MaRIA <11;
inactive partial MaRIA <7). Results of ICC analysis were
classified as very good (coefficients, 0.81–1.00), good
(0.61–0.80), moderate (0.41–0.60), fair (0.21–0.40), and
poor (<0.21). Two-tailed P value <.05 is considered as
statistically significant. No correction for multiple testing
was applied. Receiver operating characteristics (ROC)
curves were used to determine cutoff values of contin-
uous variables.Results
Patient Population
In total, 36 of the 122 patients (30%) in the TAILORIX
trial had at least 1 MRE. The majority (31/36) had both a
baseline and week 54 MRE; these patients were analyzed
in the PD analysis to assess correlation between drug
exposure and outcomes over time. Two patients had no
baseline MRE, 2 patients had an MRE at the moment of
early termination (week 26 and week 32, respectively),
and 1 patient had no week 54 MRE. The patient
Table 1. Patient Characteristics of Patients Included in TAILORIX Trial With at Least 1 MRE and Total Evaluable TAILORIX
Cohort12 and Infliximab Exposure Data of MRE Cohort
MRE TAILORIX cohort, n ¼ 36 Total TAILORIX cohort, n ¼ 11612
Median age (IQR), y 35.7 (25.6–48.6) 30 (22–45)
Median disease duration (IQR), mo 1.5 (0.6–22.4) 7 (1–78)
Gender distribution (M/F) 18/18 58/68
Median baseline C-reactive protein (IQR), mg/L 22 (7.8–34.3) 20.0 (9.0–36.5)
Median baseline fecal calprotectin (IQR), mg/g 1501 (780–1800) 1462.5 (726–1800)
Median CDAI (IQR) 282 (246–321) 280 (236–321)
Dosing regimen13 (%) Dosing regimen 1: 39 Dosing regimen 1: 36.9
Dosing regimen 2: 33 Dosing regimen 2: 30.3
Control group: 27.8 Control group: 32.8
Median yearly infliximab dose per body weight (only in
patients reaching week 54) (IQR), mg/kg/y
55.31 (44.9–67.8)
Median infliximab trough level week 14 (IQR), mg/mL 5.8 (3–8)
Median infliximab trough level week 54 (IQR), mg/mL 6.5 (4–11)
Infliximab trough levels >2 mg/mL at any time point (%) 24/36 (67)
Infliximab trough levels >3 mg/mL at any time point (%) 19/36 (53)
Infliximab trough levels >5 mg/mL at any time point (%) 9/36 (25)
Infliximab trough levels >7 mg/mL at any time point (%) 4/36 (11)
Need for dose adjustment (%) 21/36 (58)
CDAI, Crohn’s disease activity index; IQR, interquartile range; MRE, magnetic resonance enterography; TAILORIX, randomized controlled trial investigating
tailored treatment with infliximab for active luminal Crohn’s disease.





















































































433characteristics are presented in Table 1. As per inclusion
criteria of the TAILORIX trial, all patients had moderate

















450Magnetic Resonance Enterography Results
From the 69 MREs included in the study, in total 53
MREs had discrepancy between the 2 CRs in at least 1
segment based on the prior established threshold. A total
of 123 segments (123/414, 29.7%) therefore needed
adjudication. Of these segments 53% had inactive dis-
ease, and 47% had active disease of which 60% had
severe disease. The ileal (n ¼ 27, 63% active disease)
and the sigmoidal segments (n ¼ 28, 68% inactive dis-
ease) needed most adjudications. There was no differ-
ence in the number of studies with discrepancy between
baseline (n ¼ 27) and week 54 (n ¼ 24). Overall, on the
basis of the ICC analysis the reliability of the scoring of
the different readers was moderate to good at baseline.Table 2. Intraclass Correlation Between the 2 Random
Readers
Segment Week 0 Week 54
Ileum 0.746 (P < .0001) 0.671 (P ¼ .002)
Ascending colon 0.792 (P < .0001) 0.249 (P ¼ .231)
Transverse colon 0.751 (P < .0001) 0.434 (P ¼ .076)
Descending colon 0.514 (P ¼ .021) 0.177 (P ¼ .311)
Sigmoid colon 0.602 (P ¼ .004) –0.133 (P ¼ .626)
Rectum 0.726 (P ¼ .001) 0.688 (P ¼ .002)
NOTE. Results of ICC analysis were classified as very good (coefficients,
0.81–1.00), good (0.61–0.80), moderate (0.41–0.60), fair (0.21–0.40), and poor
(<0.21).














464At week 54 the correlation was only good in the ileum
and rectum (Table 2).
The radiologic response and remission rate at week
54 were 36.4% and 30.3%, respectively. The results of
the final MaRIA scores per segment are shown in
Supplementary Figure 1A and B. There was a significant
decrease in the median global MaRIA score from baseline
to the end of the study from 53 (IQR, 42–73) to 43 (IQR,
28–53) (P ¼ .001).
In patients with active disease at baseline, the
segmental radiologic remission rate in the ileum was
only 25%. The segmental radiologic remission rates were
higher in the colonic segments (70% ascending, 80%
transverse, 87% descending, 75% sigmoid, and 44%
rectum) (Supplementary Figure 1C). In all segments
apart from the rectum there was a significant decrease in
median segmental MaRIA score at week 54 compared
with baseline.
Correlation Between Radiology and Endoscopy
Endoscopic remission (CDEIS <3) was achieved in a
much higher proportion of patients (71%) than radiologic
remission. There was a correlation between the global
MaRIA and the CDEIS (continuous variables) at baseline
(k ¼ 0.46; P ¼ .008). At week 54 no correlation was seen
between the CDEIS and the global MaRIA score (k ¼ 0.06;
P ¼ .75). The reason for the absence of any correlation at
week 54 was the floor phenomenon that was seen in pa-
tientswith endoscopic remission (CDEIS<3)who still had
high MaRIA scores (Figure 1). When correlating endo-
scopic and radiologic remission (categorical variables) in
patients at week 54, no association was seen when using
either CDEIS <3 (P ¼ .107) or CDEIS <4 (P ¼ .06) as
definition of endoscopic remission.6 August 2020  6:29 am  ce CLR
Figure 1. Correlation between the CDEIS and MaRIA score at baseline (k ¼ 0.46; P ¼ .008) and week 54 (k ¼ 0.06; P ¼ .75);
trend line (full line), 95% confidence interval (dotted line). CDEIS, Crohn’s Disease Endoscopic Index of Severity; MaRIA,
Magnetic Resonance Index of Activity.
























































































552Pharmacodynamics of Infliximab and
Radiologic Response and Remission
Radiologic remission at week 54 was correlated with
infliximab trough levels at week 14 (P ¼ .049). On the
basis of a ROC analysis infliximab trough level value of
7.8 mg/mL at week 14 was identified as cutoff to predict
radiologic remission over time (area under the curve
0.74; sensitivity 75%; specificity 86%; negative predic-
tive value 90%; and positive predictive value 67%)Figure 2. Receiver operating characteristics curve indicating infl
associated with (A) radiologic remission at week 54 (area under
predictive value 90% and positive predictive value 67%); (B) wi
sensitivity 70%; and specificity 90%; negative predictive value
FLA 5.6.0 DTD  YJCGH57170_proof (Figure 2A). Radiologic response at week 54 was corre-
lated with infliximab trough levels at week 14 (P ¼ .048)
and with continuous pharmacologic response (infliximab
trough levels >5.0 mg/mL at all time points) (P ¼ .034).
An ROC-based infliximab trough level cutoff value of 7.8
mg/mL was identified (area under the curve 0.73;
sensitivity 70%; specificity 90%; negative predictive
value 86%; and positive predictive value 78%) for being
predictive for radiologic response (Figure 2B). There was
a numerically but not statistically significant differenceiximab trough level cutoff value of 7.8 mg/mL at week 14 being
the curve 0.74; sensitivity 75%; and specificity 86%; negative
th radiologic response at week 54 (area under the curve 0.73;
86% and positive predictive value 78%).





























Figure 3. Radiologic remission (A) and response (B) at week 54 per infliximab (IFX) trough level (TL) quartile at week 14.
Significantly higher radiologic response rate for the highest quartile (P ¼ .03).


































































































678in infliximab trough levels at week 54 among patients
with or without radiologic remission (P ¼ .13)
(Supplementary Figure 2). When looking at the inflix-
imab trough levels per quartile at week 14, patients in
the highest quartile had the highest radiologic response
(P ¼ .03) and remission (P ¼ .06) rate at week 54
(Figure 3). Comparing patients with both endoscopic and
radiologic remission (median infliximab trough level, 8.5;
IQR, 4.6–10.4) with patients with only endoscopic
remission (median infliximab trough level, 5.8; IQR,
2.7–6.5), a numeric but no statistically significant dif-
ference was seen in the infliximab trough levels at week
14 (P ¼ .095); no difference was seen at week 54 (P ¼
.35). A subgroup of 21 patients had dose escalation
during maintenance therapy with infliximab. In this
subgroup continuous pharmacologic response (inflix-
imab >7 mg/mL at all time points) was associated with
radiologic response (P ¼ .039) and remission (P ¼ .019).
No difference was seen in the radiologic remission (P ¼
.59) or response (P ¼ .76) rates comparing patients with


















This substudy of the prospective TAILORIX study
shows that radiologic remission and response can be
achieved with infliximab in patients with early luminal
CD, although to a much lower extent than endoscopic
remission. Infliximab trough level of 7.8 mg/mL at the
end of induction (week 14) was associated with both
endoscopic response and remission. A continuous high
infliximab exposure (infliximab >5 mg/mL at all time
points) was associated with radiologic response. This
study confirms the exposure-response relationship of
infliximab for radiologic remission. Previously an
observational cross-sectional study showed association
between adalimumab levels and bowel wall thickness
based on intestinal ultrasound.18 Several studies haveFLA 5.6.0 DTD  YJCGH57170_proof shown the exposure-response relationship for infliximab
with endoscopic remission. A post hoc analysis of the
Active Ulcerative Colitis Trials 1 and 2 showed that
infliximab levels of 5.1 mg/mL and 6.7 mg/mL at week 14
were associated with endoscopic improvement and
remission at week 30, respectively.19 Also infliximab
maintenance trough levels 7.5 mg/mL are associated
with long-term endoscopic response in ulcerative coli-
tis.20 Although proactive therapeutic drug monitoring is
not supported by robust evidence at this stage,12,13,21–23
our results do suggest that optimal induction dosing
could improve the outcomes of the patient. Moreover, in
patients with dose adjustments maintenance infliximab
trough levels >7 mg/mL were associated with radiologic
remission. Because radiologic remission is more difficult
to achieve than endoscopic remission, higher drug
exposure might be needed to reach this target.
At baseline there was a correlation between the
endoscopic and radiologic disease activity that is in line
with prior observations for MaRIA and other MRE
scores.24 However, at week 54 there was a striking
disconnect between endoscopic and radiologic remis-
sion, suggesting that radiologic remission is a more
difficult target to reach. Less than half of the patients
with endoscopic remission achieved radiologic remis-
sion. Data suggest that radiologic healing implies favor-
able clinical long-term outcomes.8–10 Although it might
be difficult to discriminate chronic bowel damage from
active disease on MRE,25 this is not applicable to our
cohort. With a median disease duration of 1.5 months we
do not expect a high burden of bowel damage. Other
studies showed better correlation between endoscopic
and radiologic remission. In the original development
cohort of the MaRIA score an optimal correlation was
seen between MaRIA and CDEIS (r ¼ 0.82, P < .001), but
74% of this cohort had active endoscopic disease.
Furthermore, the scoring methodology was not the same
in the original MaRIA article compared with the meth-
odology used in the current study (different CDEIS6 August 2020  6:29 am  ce CLR




















































































































812calculation, blinding of the endoscopist, number of ra-
diologists involved). Better correlation is also seen when
using less robust scoring of radiologic remission such as
in the pediatric ImageKids study,26 in which the defini-
tion of radiologic remission was based on a visual
analogue scale indicating the radiologist global assess-
ment. In this study there was a match of endoscopic and
radiologic remission in 69% of the patients, and only a
minority of the patients had persisting radiologic signs of
disease activity in absence of endoscopic lesions (6%).
Efforts have been made to minimize the limitations of the
current MaRIA score, leading to a more simplified
version that correlates strongly with the CDEIS.27 Of
note, there is clear difference in radiologic healing rate
according to the location of the disease. Colonic segments
have higher radiologic healing rates than the active dis-
ease located in the ileum. These findings are in line with
what is seen in this cohort on an endoscopic level (un-
published data, Riviere et al, UEGW 2019).
Our study has several strengths. First, a robust meth-
odology for the central reading of the MREs was applied,
with random allocation of the MREs to 6 experienced ra-
diologists. A low threshold was set for the need for adju-
dication, resulting in an optimal scoring. Second, this is a
unique cohort of patients with prospectively collected
clinical, pharmacologic, endoscopic, and radiologic data.
Our study also has some limitations. The patient cohortwas
relatively small, with only 36 patients included of which 31
had baseline and week 54 MRE; however, this is counter-
balanced by the fact that we used objective endpoints such
as the infliximab trough levels and radiologic healing in
luminal CD. Of note, different dose adjustment regimens
were possible in the TAILORIX trial. However, in this study
all patients had an identical induction regimen with inflix-
imab. Furthermore, we focused not on the dosing as such
but on the effective drug exposure based on the infliximab
trough levels. Third, MREswere performed on the different
MR systems with variable performance. This could indeed
influence the quality of the scoring and the inter-rater
variability. In addition, it is striking that the inter-rater
variability was mainly high in the colonic segments. That
can be explained by poorer performance of radiologic
scoring in the colon compared with the ileum. By using a
stringent protocol for the imaging and a balanced central
readingmethodology, we couldminimize the impact of this
variance. One could argue that the correlation between
endoscopic and radiologic disease activity might be better
when applying more thorough CR training and optimizing
the MRE sequences, in particular T2-fat saturation. Finally,
we found no significant association between the infliximab
trough level at week 14 and the endoscopic outcome. This
comparison between the target trough levels for the
different outcomes is not possible.
In conclusion, this prospective study indicates the
exposure-response relationship for infliximab for radio-
logic response and remission in luminal CD. Adequate
infliximab trough levels at the end of induction are
associated with beneficial radiologic outcomes at 1 year.FLA 5.6.0 DTD  YJCGH57170_proof The target of radiologic remission is achievable but to a
lower extent compared with endoscopic remission.
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Supplementary Figure 1. Evolution of radiologic activity over time. (A) Box plot of segmental MaRIA score at baseline, (B) box
plot of segmental MaRIA score at week 54 (1 dot per patient, bars ¼ mean with standard error of the mean), (C) evolution of
number of patients with active disease per segment (MaRIA score 7), and evolution in median segmental MaRIA score from
baseline to week 54 in patients with active segmental disease (decrease all P < .02, except rectum P ¼ .16). IQR, interquartile
range; MaRIA, Magnetic Resonance Index of Activity; MRE, magnetic resonance enterography.





















































































































Supplementary Figure 2. Infliximab trough level at week 54
in patients with and without radiologic remission at week 54
(P ¼ .13) (1 dot per patient, bars ¼ mean with standard error
of the mean).
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